Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
6.64 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 44.575 | 39.681 | 10 | 3.413 | 1.711 |
| Cost of Revenue
| 51.087 | 48.275 | 9.104 | 63.319 | 45.809 |
| Gross Profit
| -6.512 | -8.594 | 0.896 | -59.906 | -44.098 |
| Gross Profit Ratio
| -0.146 | -0.217 | 0.09 | -17.552 | -25.773 |
| Reseach & Development Expenses
| 232.726 | 155.696 | 135.271 | 63.319 | 45.809 |
| General & Administrative Expenses
| 110.822 | 81.599 | 57.682 | 25.258 | 18.951 |
| Selling & Marketing Expenses
| 10.399 | 0 | 0 | 0 | 0 |
| SG&A
| 110.822 | 81.599 | 57.682 | 25.258 | 18.951 |
| Other Expenses
| -1.087 | -0.162 | -0.178 | -0.549 | -0.608 |
| Operating Expenses
| 343.548 | 237.133 | 192.775 | 88.028 | 64.152 |
| Operating Income
| -350.06 | -245.727 | -182.775 | -84.615 | -62.441 |
| Operating Income Ratio
| -7.853 | -6.193 | -18.278 | -24.792 | -36.494 |
| Total Other Income Expenses Net
| 17.932 | 6.251 | -3.704 | -2.391 | 0.562 |
| Income Before Tax
| -332.128 | -239.476 | -186.479 | -87.006 | -61.879 |
| Income Before Tax Ratio
| -7.451 | -6.035 | -18.648 | -25.493 | -36.165 |
| Income Tax Expense
| -4.062 | -0.055 | -8.405 | 0.876 | 0.646 |
| Net Income
| -328.066 | -239.421 | -178.074 | -87.882 | -62.525 |
| Net Income Ratio
| -7.36 | -6.034 | -17.807 | -25.749 | -36.543 |
| EPS
| -1.58 | -1.36 | -1.05 | -0.53 | -0.38 |
| EPS Diluted
| -1.58 | -1.36 | -1.05 | -0.53 | -0.38 |
| EBITDA
| -317.595 | -245.727 | -182.775 | -80.321 | -58.2 |
| EBITDA Ratio
| -7.125 | -6.193 | -18.278 | -23.534 | -34.015 |